The higher-dose version of Eylea, which more than doubles the dosing interval, has been approved in Korea. With the approval, Eylea now owns the longest duration of effect among its competitors.

Bayer held a press conference in Yeouido, Seoul, on the 28th to celebrate the approval of Eylea High Dose (8mg) in Korea. Eylea is a treatment for age-related macular degeneration and diabetic macular edema developed by Bayer and Regeneron. The higher dose was approved in April of this year, nearly a decade after the lower dose (2 mg) was approved in 2013

Eylea binds to the vascular endothelial growth factor (VEGF)-A and B and growth factors in the retina, inhibiting VEGF from binding to its nati